US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by SAB Biotherapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO Highlights Data in Multiple Presentations at EASD
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
News headline image
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
< Previous 1 2 3 Next >